Dried blood spot improves global access to aquaporin‐4‐IgG testing for neuromyelitis optica
Abstract Objective This study aimed to evaluate the diagnostic accuracy of dried blood spot (DBS) compared with conventional serum Aquaporin‐4‐IgG (AQP4‐IgG) testing. Methods Prospective multicenter diagnostic study was conducted between April 2018 and October 2023 across medical centers in the Unit...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-11-01
|
| Series: | Annals of Clinical and Translational Neurology |
| Online Access: | https://doi.org/10.1002/acn3.52178 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846163978538975232 |
|---|---|
| author | Nisa Vorasoot Yahya J. Abdulrahman Farrah Mateen James P. Fryer Vyanka Redenbaugh Jessica A. Sagen Abdu K. Musubire Sarah M. Jenkins Amy P. Gorsh John J. Chen Anastasia Zekeridou Andrew McKeon Eoin P. Flanagan John R. Mills Sean J. Pittock |
| author_facet | Nisa Vorasoot Yahya J. Abdulrahman Farrah Mateen James P. Fryer Vyanka Redenbaugh Jessica A. Sagen Abdu K. Musubire Sarah M. Jenkins Amy P. Gorsh John J. Chen Anastasia Zekeridou Andrew McKeon Eoin P. Flanagan John R. Mills Sean J. Pittock |
| author_sort | Nisa Vorasoot |
| collection | DOAJ |
| description | Abstract Objective This study aimed to evaluate the diagnostic accuracy of dried blood spot (DBS) compared with conventional serum Aquaporin‐4‐IgG (AQP4‐IgG) testing. Methods Prospective multicenter diagnostic study was conducted between April 2018 and October 2023 across medical centers in the United States, Uganda, and the Republic of Guinea. Neuromyelitis optica spectrum disorder (NMOSD) patients and controls collected blood on filter paper cards along with concurrent serum samples. These samples underwent analysis using flow cytometric live‐cell‐based assays (CBA) and enzyme‐linked immunosorbent assay (ELISA) to determine AQP4 serostatus. The accuracy of AQP4‐IgG detection between DBS and serum (gold standard) was compared. Results Among 150 participants (47 cases, 103 controls), there was a strong correlation between DBS and serum samples (Spearman's correlation coefficient of 0.82). The AUC was 0.97 (95% CI: 0.92–0.99). AQP4‐IgG detection through DBS showed 87.0% sensitivity (95% CI: 0.74–0.95) and 100% specificity (95% CI: 0.96–1.00) using CBA, and 65.2% sensitivity (95% CI: 0.43–0.84) and 95.2% specificity (95% CI: 0.76–0.99) using ELISA. Serum ELISA demonstrated 69.6% sensitivity (95% CI: 0.47–0.87) and 98.4% specificity (95% CI: 0.91–0.99). The stability of DBS in detecting AQP4‐IgG persisted over 24 months for most cases. Interpretation The DBS represents a viable alternative for detecting AQP4‐IgG in resource‐limited settings to diagnose NMOSD, offering high sensitivity and specificity comparable to serum testing. Moreover, DBS has low shipping costs, is easy to administer, and is suitable for point‐of‐care testing. |
| format | Article |
| id | doaj-art-550d0b1d41f6485f821401fdab5b8cc3 |
| institution | Kabale University |
| issn | 2328-9503 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Annals of Clinical and Translational Neurology |
| spelling | doaj-art-550d0b1d41f6485f821401fdab5b8cc32024-11-18T17:52:33ZengWileyAnnals of Clinical and Translational Neurology2328-95032024-11-0111112855286510.1002/acn3.52178Dried blood spot improves global access to aquaporin‐4‐IgG testing for neuromyelitis opticaNisa Vorasoot0Yahya J. Abdulrahman1Farrah Mateen2James P. Fryer3Vyanka Redenbaugh4Jessica A. Sagen5Abdu K. Musubire6Sarah M. Jenkins7Amy P. Gorsh8John J. Chen9Anastasia Zekeridou10Andrew McKeon11Eoin P. Flanagan12John R. Mills13Sean J. Pittock14Department of Neurology Mayo Clinic Rochester Minnesota USADepartment of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USADepartment of Neurology Massachusetts General Hospital Boston Massachusetts USADepartment of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USADepartment of Neurology Mayo Clinic Rochester Minnesota USACenter of MS and Autoimmune Neurology Mayo Clinic Rochester Minnesota USADepartment of Medicine School of Medicine, College of Health Sciences, Makerere University Kampala UgandaDepartment of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics Mayo Clinic Rochester Minnesota USADepartment of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USACenter of MS and Autoimmune Neurology Mayo Clinic Rochester Minnesota USADepartment of Neurology Mayo Clinic Rochester Minnesota USADepartment of Neurology Mayo Clinic Rochester Minnesota USADepartment of Neurology Mayo Clinic Rochester Minnesota USADepartment of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USADepartment of Neurology Mayo Clinic Rochester Minnesota USAAbstract Objective This study aimed to evaluate the diagnostic accuracy of dried blood spot (DBS) compared with conventional serum Aquaporin‐4‐IgG (AQP4‐IgG) testing. Methods Prospective multicenter diagnostic study was conducted between April 2018 and October 2023 across medical centers in the United States, Uganda, and the Republic of Guinea. Neuromyelitis optica spectrum disorder (NMOSD) patients and controls collected blood on filter paper cards along with concurrent serum samples. These samples underwent analysis using flow cytometric live‐cell‐based assays (CBA) and enzyme‐linked immunosorbent assay (ELISA) to determine AQP4 serostatus. The accuracy of AQP4‐IgG detection between DBS and serum (gold standard) was compared. Results Among 150 participants (47 cases, 103 controls), there was a strong correlation between DBS and serum samples (Spearman's correlation coefficient of 0.82). The AUC was 0.97 (95% CI: 0.92–0.99). AQP4‐IgG detection through DBS showed 87.0% sensitivity (95% CI: 0.74–0.95) and 100% specificity (95% CI: 0.96–1.00) using CBA, and 65.2% sensitivity (95% CI: 0.43–0.84) and 95.2% specificity (95% CI: 0.76–0.99) using ELISA. Serum ELISA demonstrated 69.6% sensitivity (95% CI: 0.47–0.87) and 98.4% specificity (95% CI: 0.91–0.99). The stability of DBS in detecting AQP4‐IgG persisted over 24 months for most cases. Interpretation The DBS represents a viable alternative for detecting AQP4‐IgG in resource‐limited settings to diagnose NMOSD, offering high sensitivity and specificity comparable to serum testing. Moreover, DBS has low shipping costs, is easy to administer, and is suitable for point‐of‐care testing.https://doi.org/10.1002/acn3.52178 |
| spellingShingle | Nisa Vorasoot Yahya J. Abdulrahman Farrah Mateen James P. Fryer Vyanka Redenbaugh Jessica A. Sagen Abdu K. Musubire Sarah M. Jenkins Amy P. Gorsh John J. Chen Anastasia Zekeridou Andrew McKeon Eoin P. Flanagan John R. Mills Sean J. Pittock Dried blood spot improves global access to aquaporin‐4‐IgG testing for neuromyelitis optica Annals of Clinical and Translational Neurology |
| title | Dried blood spot improves global access to aquaporin‐4‐IgG testing for neuromyelitis optica |
| title_full | Dried blood spot improves global access to aquaporin‐4‐IgG testing for neuromyelitis optica |
| title_fullStr | Dried blood spot improves global access to aquaporin‐4‐IgG testing for neuromyelitis optica |
| title_full_unstemmed | Dried blood spot improves global access to aquaporin‐4‐IgG testing for neuromyelitis optica |
| title_short | Dried blood spot improves global access to aquaporin‐4‐IgG testing for neuromyelitis optica |
| title_sort | dried blood spot improves global access to aquaporin 4 igg testing for neuromyelitis optica |
| url | https://doi.org/10.1002/acn3.52178 |
| work_keys_str_mv | AT nisavorasoot driedbloodspotimprovesglobalaccesstoaquaporin4iggtestingforneuromyelitisoptica AT yahyajabdulrahman driedbloodspotimprovesglobalaccesstoaquaporin4iggtestingforneuromyelitisoptica AT farrahmateen driedbloodspotimprovesglobalaccesstoaquaporin4iggtestingforneuromyelitisoptica AT jamespfryer driedbloodspotimprovesglobalaccesstoaquaporin4iggtestingforneuromyelitisoptica AT vyankaredenbaugh driedbloodspotimprovesglobalaccesstoaquaporin4iggtestingforneuromyelitisoptica AT jessicaasagen driedbloodspotimprovesglobalaccesstoaquaporin4iggtestingforneuromyelitisoptica AT abdukmusubire driedbloodspotimprovesglobalaccesstoaquaporin4iggtestingforneuromyelitisoptica AT sarahmjenkins driedbloodspotimprovesglobalaccesstoaquaporin4iggtestingforneuromyelitisoptica AT amypgorsh driedbloodspotimprovesglobalaccesstoaquaporin4iggtestingforneuromyelitisoptica AT johnjchen driedbloodspotimprovesglobalaccesstoaquaporin4iggtestingforneuromyelitisoptica AT anastasiazekeridou driedbloodspotimprovesglobalaccesstoaquaporin4iggtestingforneuromyelitisoptica AT andrewmckeon driedbloodspotimprovesglobalaccesstoaquaporin4iggtestingforneuromyelitisoptica AT eoinpflanagan driedbloodspotimprovesglobalaccesstoaquaporin4iggtestingforneuromyelitisoptica AT johnrmills driedbloodspotimprovesglobalaccesstoaquaporin4iggtestingforneuromyelitisoptica AT seanjpittock driedbloodspotimprovesglobalaccesstoaquaporin4iggtestingforneuromyelitisoptica |